Do analysts recommend RFL or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ADXS or CPIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ADXS or VANI?

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 169.78%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts clearly believe Vivani Medical is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ADXS or VANI more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Vivani Medical N/A -191.05% -70.91%

Do analysts recommend AARD or ADXS?

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 151.37%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is AARD or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Ayala Pharmaceuticals N/A N/A N/A

Do analysts rate ADXS or VTVT?

vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 74.48%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 vTv Therapeutics 2 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ADXS or VTVT more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A vTv Therapeutics N/A -6.27% -5.06%

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 08/28/2026

Compare

ADXS vs. RFL, CPIX, VANI, AARD, and VTVT

Should you buy Ayala Pharmaceuticals stock or one of its competitors? Ayala Pharmaceuticals's main competitors and comparable companies include Rafael (RFL), Cumberland Pharmaceuticals (CPIX), Vivani Medical (VANI), Aardvark Therapeutics (AARD), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ayala Pharmaceuticals compare to Rafael?

Rafael (NYSE:RFL) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Rafael's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Rafael	Neutral
Ayala Pharmaceuticals	Neutral

Ayala Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Ayala Pharmaceuticals' return on equity of 0.00% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Ayala Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Rafael has higher earnings, but lower revenue than Ayala Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	144.13	-$30.52M	-$0.68	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

11.3% of Rafael shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rafael has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Summary

Rafael and Ayala Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Cumberland Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Ayala Pharmaceuticals has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Ayala Pharmaceuticals' return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than Ayala Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Cumberland Pharmaceuticals	$44.52M	2.25	-$2.84M	-$0.71	N/A

In the previous week, Cumberland Pharmaceuticals had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Cumberland Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Cumberland Pharmaceuticals	Positive

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cumberland Pharmaceuticals beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Vivani Medical?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

In the previous week, Vivani Medical had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Vivani Medical and 0 mentions for Ayala Pharmaceuticals. Vivani Medical's average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Vivani Medical	Positive

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 53.3% of Vivani Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Vivani Medical has lower revenue, but higher earnings than Ayala Pharmaceuticals. Vivani Medical is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Vivani Medical	N/A	-191.05%	-70.91%

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 169.78%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts clearly believe Vivani Medical is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Vivani Medical beats Ayala Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Aardvark Therapeutics had 28 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 28 mentions for Aardvark Therapeutics and 0 mentions for Ayala Pharmaceuticals. Aardvark Therapeutics' average media sentiment score of 0.04 beat Ayala Pharmaceuticals' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Ayala Pharmaceuticals	Neutral

Ayala Pharmaceuticals' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Ayala Pharmaceuticals	N/A	N/A	N/A

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 151.37%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ayala Pharmaceuticals has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Aardvark Therapeutics has a beta of 3.8, meaning that its stock price is 280% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Summary

Aardvark Therapeutics beats Ayala Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, vTv Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Ayala Pharmaceuticals. vTv Therapeutics' average media sentiment score of 0.94 beat Ayala Pharmaceuticals' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
vTv Therapeutics	Positive

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

vTv Therapeutics has a consensus price target of $55.83, suggesting a potential upside of 74.48%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
vTv Therapeutics	N/A	-6.27%	-5.06%

vTv Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
vTv Therapeutics	$1.02M	123.61	-$26.97M	-$1.06	N/A

Summary

vTv Therapeutics beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.79M	$12.20B	$7.20B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	10.96%
P/E Ratio	-0.08	785.16	272.60	25.50
Price / Sales	11.05	758.14	626.13	97.73
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	-0.29	10.54	11.03	6.34
Net Income	-$48.07M	$2.83B	$3.47B	$349.45M
7 Day Performance	N/A	-0.93%	0.12%	-0.67%
1 Month Performance	N/A	5.14%	8.14%	4.48%
1 Year Performance	N/A	5.97%	24.11%	14.94%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
RFL Rafael	0.125 of 5 stars	$2.61 +10.1%	N/A	+72.9%	$135.72M	$920K	N/A	20	High Trading Volume
CPIX Cumberland Pharmaceuticals	0.8032 of 5 stars	$8.64 -0.1%	N/A	+91.7%	$129.45M	$44.30M	N/A	80	Gap Down
VANI Vivani Medical	3.1706 of 5 stars	$1.42 +1.4%	$3.75 +164.1%	+20.9%	$128.09M	N/A	N/A	20
AARD Aardvark Therapeutics	2.8527 of 5 stars	$5.85 -11.6%	$15.33 +162.1%	-26.5%	$128.02M	N/A	N/A	18

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. RFL, CPIX, VANI, AARD, and VTVT

How does Ayala Pharmaceuticals compare to Rafael?

Summary

How does Ayala Pharmaceuticals compare to Cumberland Pharmaceuticals?

Summary

How does Ayala Pharmaceuticals compare to Vivani Medical?

Summary

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. RFL, CPIX, VANI, AARD, and VTVT

How does Ayala Pharmaceuticals compare to Rafael?

Does the media prefer RFL or ADXS?

Is RFL or ADXS more profitable?

Do analysts recommend RFL or ADXS?

Which has higher earnings and valuation, RFL or ADXS?

Do insiders & institutionals believe in RFL or ADXS?

Which has more risk and volatility, RFL or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Cumberland Pharmaceuticals?

Is ADXS or CPIX more profitable?

Which has more volatility & risk, ADXS or CPIX?

Which has higher earnings and valuation, ADXS or CPIX?

Does the media refer more to ADXS or CPIX?

Do insiders and institutionals hold more shares of ADXS or CPIX?

Do analysts rate ADXS or CPIX?

Summary

How does Ayala Pharmaceuticals compare to Vivani Medical?

Does the media refer more to ADXS or VANI?

Do insiders and institutionals believe in ADXS or VANI?

Which has more volatility & risk, ADXS or VANI?

Which has stronger valuation & earnings, ADXS or VANI?

Is ADXS or VANI more profitable?

Do analysts rate ADXS or VANI?

Summary

How does Ayala Pharmaceuticals compare to Aardvark Therapeutics?

Does the media prefer AARD or ADXS?

Is AARD or ADXS more profitable?

Do analysts recommend AARD or ADXS?

Do institutionals and insiders have more ownership in AARD or ADXS?

Which has higher valuation & earnings, AARD or ADXS?

Which has more risk & volatility, AARD or ADXS?

Summary

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Does the media prefer ADXS or VTVT?

Do institutionals and insiders hold more shares of ADXS or VTVT?

Which has more risk and volatility, ADXS or VTVT?

Do analysts rate ADXS or VTVT?

Is ADXS or VTVT more profitable?

Which has better earnings & valuation, ADXS or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools